# A Study to Evaluate the Drug-Drug Interaction of EDP-323 With Midazolam, Caffeine, and Rosuvastatin in Healthy Participants

> **NCT06917508** · PHASE1 · COMPLETED · sponsor: **Enanta Pharmaceuticals, Inc** · enrollment: 24 (actual)

## Conditions studied

- RSV Infection
- Drug Drug Interaction

## Interventions

- **DRUG:** EDP-323
- **DRUG:** Midazolam
- **DRUG:** Caffeine
- **DRUG:** Rosuvastatin

## Key facts

- **NCT ID:** NCT06917508
- **Lead sponsor:** Enanta Pharmaceuticals, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-03-13
- **Primary completion:** 2025-06-06
- **Final completion:** 2025-06-13
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2025-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06917508

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06917508, "A Study to Evaluate the Drug-Drug Interaction of EDP-323 With Midazolam, Caffeine, and Rosuvastatin in Healthy Participants". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT06917508. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*